InvestSMART

Epsilon Healthcare Limited (ASX:EPN)

ALERT: Price-sensitive ASX Announcement for EPN
Current share price for EPN : $0.023 -0.009 (-28.13%)+
Announcement
Release
28 Jan 2026 11:27AM
Price at Release
$0.032
Full Release
download
Summary
Epsilon Healthcare Limited (ASX: EPN) reported strong financial performance for the quarter ending 31 December 2025, with a notable 96% year-on-year increase in quarterly receipts, totaling $2.891 million. The company also recorded annual receipts of $9.175 million, up 71% from the previous year. This growth is attributed to sustained demand across its operating subsidiaries, including contract development and manufacturing operations. Epsilon was reinstated to ASX quotation on 19 December 2025, marking a significant milestone. The company received $299K from the R&D tax incentive during the quarter and plans to expand its operations with a new high-street pharmacy in early 2026. The company ended the quarter with $242,000 in cash and had $4.545 million in total financing facilities, with $2 million available for future use.
Key Points
  • Epsilon Healthcare Limited (ASX: EPN) reported a record performance for the quarter ended 31 December 2025.
  • The company achieved a significant 96% increase in quarterly receipts year-on-year.
  • Epsilon Healthcare was reinstated to ASX quotation on 19 December 2025.
  • Financial receipts for the quarter were $2.891 million, and for the year, they amounted to $9.175 million.
  • The December quarter included a receipt of $299K from the R&D tax incentive.
  • Epsilon’s contract development and manufacturing operations saw substantial growth.
  • The company plans to open a new high-street pharmacy in Q1 2026.
  • The company ended the quarter with $242,000 in cash and cash equivalents.
  • Epsilon has a total of $4.545 million in financing facilities, with $2 million available for use.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.